Quantifying beta cell function in the preclinical stages of type 1 diabetes

Diabetologia. 2023 Dec;66(12):2189-2199. doi: 10.1007/s00125-023-06011-5. Epub 2023 Sep 15.

Abstract

Clinically symptomatic type 1 diabetes (stage 3 type 1 diabetes) is preceded by a pre-symptomatic phase, characterised by progressive loss of functional beta cell mass after the onset of islet autoimmunity, with (stage 2) or without (stage 1) measurable changes in glucose profile during an OGTT. Identifying metabolic tests that can longitudinally track changes in beta cell function is of pivotal importance to track disease progression and measure the effect of disease-modifying interventions. In this review we describe the metabolic changes that occur in the early pre-symptomatic stages of type 1 diabetes with respect to both insulin secretion and insulin sensitivity, as well as the measurable outcomes that can be derived from the available tests. We also discuss the use of metabolic modelling to identify insulin secretion and sensitivity, and the measurable changes during dynamic tests such as the OGTT. Finally, we review the role of risk indices and minimally invasive measures such as those derived from the use of continuous glucose monitoring.

Keywords: Diabetes stages; Metabolic modelling; Oral glucose tolerance test; Oral minimal model; Review; Stage 1 type 1 diabetes; Stage 2 type 1 diabetes; Type 1 diabetes.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Blood Glucose / metabolism
  • Blood Glucose Self-Monitoring
  • Diabetes Mellitus, Type 1* / metabolism
  • Diabetes Mellitus, Type 2* / metabolism
  • Glucose Tolerance Test
  • Humans
  • Insulin / metabolism
  • Insulin Resistance* / physiology
  • Insulin-Secreting Cells* / metabolism

Substances

  • Blood Glucose
  • Insulin